Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser H. Hanna, Paul A. Bunn, Frances A. Shepherd et al.|Journal of Clinical Oncology|2004Cited by 2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Yan Sun et al.|The Lancet|2008Cited by 1.2k
[Management of adverse effects of targeted therapy toxicities in oncology].Elodie Coquan, Florence Joly, Patrick Henri et al.|PubMed|2012Cited by 3